<DOC>
	<DOCNO>NCT00724672</DOCNO>
	<brief_summary>This 14-week study observe gene expression certain immune cell patient rheumatoid arthritis receive etanercept , infliximab , adalimumab . Patients National Institute Rheumatology Physiotherapy , Budapest , already schedule receive anti-TNF agent ask participate study . Patients receive treatment ( etanercept , infliximab , adalimumab ) schedule , blood sample collect study analyze laboratory . Patient 's response treatment also study base x-rays examination .</brief_summary>
	<brief_title>A Study Immune Cells Patients With Rheumatoid Arthritis During Different Types Anti-TNF Alpha Treatments ( Study P05521 )</brief_title>
	<detailed_description>Only patient - regardless study - schedule permitted receive anti-TNF-alpha treatment RA ask participate . No patient recruit sake study . The prescribing physician influence study form anti-TNF-alpha therapy select .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must active RA ( DAS28 &gt; 5.1 ) Must xray evidence erosive disease , Must eligible never receive antiTNF treatment , Must fulfill 1987 criterion American College Rheumatology classification criterion diagnosis RA , least 3 month , Must fail standard therapy ( methotrexate leflunomide ) . Must woman pregnant breastfeeding , Must history malignancy , Must active infection , Must prone infection , Must tuberculosis , hepatitis B , hepatitis C , HIV , Must septic arthritis native prosthetic joint within last 12 month , Must NYHA grade 3 4 heart failure , Must history demyelinate disease systemic lupus erythematosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>